Abstract (246/250 words) 23
To evaluate the exposure-response relationships for efficacy and safety of voriconazole and 24 anidulafungin in adult patients with invasive aspergillosis (IA), a population pharmacokinetic-25 pharmacodynamic (PK-PD) analysis was performed with data from a phase 3, prospective, 26 double-blind, comparative study evaluating voriconazole and anidulafungin combination therapy 27 versus voriconazole (and placebo) monotherapy. Anidulafungin/placebo treatment duration was 28 2 to 4 weeks and voriconazole treatment duration was 6 weeks. Efficacy (6-week all-causality 29 mortality and 6-week global response, [n = 176] ) and safety (hepatic [n = 238] , visual [n = 199] Estimation of exposure parameters. Population PK models describing anidulafungin 121 and voriconazole plasma concentration data from this study were reported separately (17) . 122
Individual anidulafungin AUC over a 24-h dosing interval (AUC 0-24 ) and C min were 123 estimated based on individual PK parameters from the anidulafungin population PK model 124 developed from the data for this study (17), and used for both safety and efficacy analyses. values over the entire treatment period were used. When patients experienced an AE, the AUC 0-139 12 and C min from the onset day of this AE were used. When using the single-panel analysis 140 approach, for patients experiencing multiple AEs, the AUC 0-12 and C min associated with the first 141 AE occurrence were used. Note that because of the q12h dosing schedule for voriconazole, two 142 AUC 0-12 and C min values on each day were available. Since most of AEs did not have onset time 143 recorded, average AUC 0-12 and C min values on the AE onset day were used for analysis. 144
Population PK-PD analysis. All the efficacy and safety data were evaluated as binary 145 data using a logistic regression model in the NONMEM system (Version 7.1.2, Icon 146 Development Solutions, Ellicott City, MD) with the second order conditional (Laplacian) 147 estimation method. The graphic processing of the data and the NONMEM output was performed 148 with R (version 2.12.2). 149
The efficacy population included the modified intent-to-treat (mITT) patients (with 150 independent Data Review Committee [DRC] confirmed diagnosis of probable or proven IA, and 151 received at least one study dose), who had concentration data available. Note that 5 mITT 152 patients with less than 3 days of study treatment were excluded from the efficacy analysis as they 153 had insufficient exposure to study drug(s). The safety population included all patients (with 154 diagnosis of possible, probable or proven IA) who received at least one study dose and had 155 concentration data available. 156
Each efficacy endpoint (6-week all-causality mortality and 6-week global response) and8 predictors. Other covariates (e.g., CYP2C19 genotype status, age, weight, body mass index 160
[BMI], sex and race) were also examined in each analysis. Furthermore, baseline neutropenia 161 status (as binary data) and AUC/MIC were explored as potential predictors for efficacy. 162
Anidulafungin treatment duration ("Duranid") was also tested as a potential predictor for 163 efficacy. Since anidulafungin treatment may have been stopped at the investigator's discretion 164 during week 3 and week 4 or because the subject expires, "Duranid" becomes a potential 165 covariate of response. It is acknowledged that caution should be taken when considering 166 "Duranid" as a potential covariate. 167
The effects of potential covariates on both efficacy and safety endpoints were first 168 explored graphically. If a visual trend was observed, the covariate was selected for further 169 evaluation using logistic regression modeling. The model described the observed trend in the 170 probability of experiencing an AE or meeting an efficacy endpoint (equations below). Where the probability of an event for an individual i is given by p i , λ i is the logit, which 175 is the natural log of the odds ratio, θ 1 is the baseline probability of success/AE occurrence, θ 2 is 176 the log odds contribution of drug exposure (AUC, C min or AUC/MIC), and other covariates 177 ("factor") may be added in with additional adjustments (θ n ) to the baseline probability. 178
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Since each individual contributed only one observation for each endpoint in the single-179 panel analysis, the individual random effect (η i ) was fixed at a value of zero. Even with the 180 multiple-panel AE analysis, the majority of the patients still had one response only. The 181 individual random effect (η i ) was not estimated and also fixed at a value of zero. 182
Model selection was based on goodness-of-fit criteria including the objective function 183 value (OFV), precision of parameter estimates and diagnostic plots. The acceptance criteria for 184 inclusion of a covariate into the model as a significant predictor included reduction in OFV of at 185 least 7.88 (corresponding to a p-value of 0.005 with one degree of freedom, difference of log-186
likelihoods from nested models is approximately asymptotically χ 2 distributed), and a reduction 187 (or at least no increase) in the unexplained variability in the model when estimated. Estimates of 188 parameter precision were obtained from the asymptotic standard errors of the estimated 189 parameters and described as percent relative standard error (%RSE). 190
RESULTS 191
Data for analysis. There were 176 mITT patients with exposure and efficacy data pairs 192 (80 in the combination group). The data pairs used for exposure-safety analysis are summarized 193 in Table 1 . Each AE dataset included 161 patients who had no hepatic, visual, or psychiatric 194
AEs. 195
Exposure-efficacy analysis. The demographics and exposure parameters tested as 196 potential covariates (predictors) are summarized in Table S1 (supplemental material). 197 however, the rate of SURV6 appeared to be lower in patients with higher voriconazole exposure 210 (e.g., C min >5 μg/mL) although the number of patients in this category was low (n = 12). This 211 might be explained by that patients with poor prognosis may have significantly compromised 212 body function (e.g., multi-organ failure, decreased hepatic function, etc.), leading to inadequate 213 elimination of voriconazole from the body. In addition, the rate of SURV6 in patients with 214 voriconazole C min ≤2 μg/mL was similar to or even higher than that in patients with higher C min . 215
The rate of SURV6 tended to decrease slightly as age increased; however, age was not 216 identified as a significant predictor. The CYP2C19 genotype status, neutropenic status, body 217 weight, BMI, sex and race had no apparent association with SURV6. 218
(ii) Global response at week 6. Graphical examinations of potential covariates are 219 presented in Figure S1 (supplemental material). A slightly positive trend was observed for 220 anidulafungin treatment duration (with the same caveats mentioned previously), sex, race, 221 CYP2C19 genotyping status and baseline neutropenic status (male, Asian, CYP2C19 PMs and 222 neutropenic patients appeared to have lower success rate). However, none of the potential 223 on August 29, 2017 by guest http://aac.asm.org/ Downloaded from covariates were identified as significant predictors for global response. Similar to 6-week 224 survival rate, the success rate of global response appeared to be lower in patients with higher 225 voriconazole exposure, and this was observed in both treatment groups ( Figure S1 ). The 226 explanation for SURV6 may also be applicable here. 227
(iii) The PK-PD index (AUC/MIC). Due to technical challenges, the fungal isolates 228 were obtained in a very small subset of IA patients, which is not unexpected. A total of 23 229 patients had AUC/MIC values available and 11 of them were from the combination group. 230
Likely due to limited data on MIC values against Aspergillus spp., no apparent association was 231 identified between AUC/MIC and efficacy endpoints (data on file). 232
Exposure-safety analysis. (i) Hepatic AEs. The demographics and exposure parameters 233 tested as potential covariates for treatment-related hepatic AEs are summarized in Table S2  234 (supplemental material). The route of administration of voriconazole was not tested as a potential 235 covariate in relation to hepatic AEs. Since a few cases (e.g., hepatic failure, hepatotoxicity and 236 hepatitis toxic) were considered relatively severe and different from other typical hepatic AEs, 237 they were examined separately to ensure no specific trend was present (Table S3, supplemental  238 material). Five out of 6 events were reported from the combination group, and 4 of them (all 239 from combination group) had voriconazole C min exceeding 4.5 μg/mL. Note that a total of 54 240 patients had voriconazole C min exceeding 4.5 μg/mL in the dataset. 241
Graphical examinations of exposure parameters as potential predictors for treatment-242 related hepatic AE occurrence with single-panel data are presented in Figure 3 . Both 243 voriconazole and anidulafungin C min as well as corresponding AUC were identified as being 244 significant predictors for treatment-related hepatic AE occurrence in the combination group 245 (Table 2) suggests there may be an additive or synergistic effect on the risk of experiencing at least one 248 treatment-related hepatic AE when voriconazole and anidulafungin were used in combination. 249
Moreover, in the monotherapy group, the rate of hepatic AEs appeared to be lower in patients 250 with higher voriconazole exposure (e.g., C min >5 μg/mL) although the number of patients in this 251 category was low (n = 16). 252
For the multiple-panel analysis of treatment-related hepatic AEs, the difference in 253 observed trends from the single-panel data was the higher AE rate in the anidulafungin low 254 exposure category (C min ≤2 μg/mL). Nonetheless, similar results were obtained (data on file). Table 3 . For instance, with single-panel data, when voriconazole 262 C min was increased by 1 µg/mL steps (range: 1 -9 µg/mL) in the presence of anidulafungin (e.g., 263 median C min = 2.6 µg/mL), on average, the risk of experiencing at least one treatment-related 264 hepatic AE would be increased by 5-8%. Similarly, when anidulafungin C min was increased by 1 265 µg/mL steps (range: 1 -8 µg/mL) in the presence of voriconazole (e.g., median C min = 3 µg/mL), 266 on average, the risk of experiencing at least one treatment-related hepatic AE would be increased 267 Table S4 (supplemental material) . 279
For the single-panel data, a positive trend between voriconazole exposure and treatment-280 related psychiatric AE occurrence was observed in the combination group, but this trend was not 281 identified in the monotherapy group ( Figure S3, supplemental material) . Again, none of the 282 potential covariates were identified as significant predictors, including voriconazole exposure, 283 which marginally missed the inclusion criteria. 284
For the multiple-panel data, both voriconazole C min and AUC 0-12 were identified as being 285 significant predictors for treatment-related psychiatric AE occurrence only in the combination 286 group (Table 2) . A wide 95% confidence interval (CI) around the population prediction on 287 probability of psychiatric AE occurrence was observed when voriconazole C min exceeded 4 288 μg/mL or AUC 0-12 exceeded 60 μg.h/mL, indicating low precision on the probability prediction 289 ( Figure 5 ). This is not unexpected given the low incidence of this AE and the small number of 290 patients with high voriconazole exposures in this dataset. Based on the model prediction, when 291 on August 29, 2017 by guest http://aac.asm.org/ Downloaded from voriconazole C min was increased by 1 µg/mL steps (range: 1 -9 µg/mL) in the presence of 292 anidulafungin, on average, the risk of experiencing at least one treatment-related psychiatric AE 293 would be increased by 3-9% with very large uncertainty. 294
DISCUSSION 295
Efficacy. The primary analysis of the 277 mITT patients from this study showed that the 296 combination of anidulafungin and voriconazole was associated with a trend towards improved 297 survival compared to voriconazole monotherapy although this difference did not meet the pre-298 specified criteria for superiority (6- by the DRC as 'not evaluable'. The exposure-efficacy analysis of the subset mITT patients (n = 304 176) showed lack of positive association between drug exposures and 6-week global response 305 (GR6), which confirmed that failure of global response was not due to low drug exposures in this 306 study. 307
Moreover, the exposure-efficacy analysis could not identify a significant positive 308 association between anidulafungin and voriconazole exposures (AUC and C min ) and the 6-week 309 survival rate (SURV6), but a slightly positive trend was observed for anidulafungin exposure in 310 the combination group based on graphical examination (Figure 1 ). The dips in SURV6 and GR6 311 in the anidulafungin middle exposure category (e.g., AUC 0-24 : >80-120 μg.h/mL) were noted, 312 which could reflect a random observation (Figure 1 and Figure S1 ). No conclusion can be drawn 313 from this observation. 314 on August 29, 2017 by guest http://aac.asm.org/
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Note that in the monotherapy group, the 6-week survival rate and successful global 315 response rate appeared to be lower in patients with higher voriconazole exposure (i.e., C min >5 316 μg/mL, n = 12) (Figure 1 and Figure S1 ). This possibly is a reflection of the complex clinical 317 situation. Treatment effect is just one of the contributing factors leading to successful clinical 318 outcomes for life-threatening fungal infections (22). Patient's underlying conditions and ability 319 to respond to the treatment are also important factors influencing the clinical outcomes. The 320 assessment of the relationship between voriconazole or anidulafungin exposure and clinical 321 outcomes could be confounded by these factors. To rule out the possibility of reductions in 322 survival and global response being due to toxicities related to elevated voriconazole exposures, 323 the 9 patients in the monotherapy group, who died before day 42 with voriconazole C min >5 324 μg/mL, were assessed thoroughly (Table S5 , supplemental material). Five patients stopped the 325 voriconazole treatment at least 6 days before the death occurred, and the other 4 patients died 326 within 2 days after the last dose of voriconazole (2 of them had very short treatment duration). 327
Based on the cause of death, none of them were considered treatment related. Among them, one 328 patient had a successful 6-week global response (others died before the week 6 assessment could 329 be made). Taken together, it is unlikely that these deaths were related to voriconazole-related 330 toxicities due to exposure to high voriconazole concentrations. 331
Although the best predictor for the 6-week survival rate was anidulafungin treatment 332 duration, as stated earlier, caution in interpretation of this predictor is warranted because of the 333 caveat that patients expiring prior to week 2 would necessarily have shorter duration of therapy, 334 which could artificially inflate the effect of this covariate. 335
As described earlier, several published articles have proposed target minimum values for 336 voriconazole C min to improve clinical outcomes, such as 1 or 2 µg/mL (3, 9, (11) (12) (13) 23) . 337
However, the results from our analysis do not support these cutoffs. As shown in Figure 1 (lower  338 panel), the 6-week survival rate in IA patients with voriconazole C min ≤2 μg/mL was similar to or 339 even higher than that in patients with higher C min . A further dissemination of the lower range of 340 voriconazole C min is presented in Figure S4 . Even in patients with voriconazole C min ≤1 μg/mL, 341 the survival rate was still comparable to other exposure categories although the number of 342 patients in this category was small (n = 17 in total). This suggests that voriconazole C min does not 343 necessarily need to exceed 1 or 2 μg/mL to achieve successful clinical outcomes in IA patients. 344
Our findings on the relationship between voriconazole exposure and clinical outcomes in 345 IA patients (lack of positive association) are consistent with recently published retrospective 346
analyses of large-scale TDM data (in 108 patients) by Chu et al. (14) and that (in 264 patients) 347
by Racil et al. (15) . 348 Safety. Our analysis did not identify any positive association between voriconazole 349 exposure and hepatic, visual or psychiatric AEs in IA patients receiving voriconazole 350 monotherapy. It is also noted that in the monotherapy group, the rate of hepatic and visual AEs 351 appeared to be lower in patients with higher voriconazole exposure (e.g., C min >5 μg/mL) 352 although the number of patients in this category was low (Figure 3 and Figure S2 ). voriconazole C min to minimize treatment-related toxicity, such as 6 or 5 or even 4 µg/mL (3, 9, 363 11-13, 23), and most of them were based on the identification of the association between 364 elevated concentrations and neurologic AEs, but not hepatic AEs. These proposals were 365 recommended based on voriconazole monotherapy regimens. Again, the results from our 366 analysis do not support these cutoffs. Even in the combination group (where the positive 367 association between exposures and hepatic AEs was established), there was no steep increase in 368 the risk of having a hepatic AE as voriconazole C min increased in the presence of anidulafungin 369 (e.g., mean increase of 5-8% by 1 µg/mL increment) (Figure 4) . Hepatic AEs can be monitored 370 through routine laboratory tests and visual AEs and neurotoxicity can be observed in clinical 371 practice. Hence, it may not be essential to set up the upper threshold to a lower value if 372 voriconazole C min is used to minimize the risks of treatment related toxicity, which could lead to 373 unnecessary dose adjustments. 374
It is possible that the lack of association between voriconazole exposure and efficacy 375 and safety in the voriconazole monotherapy group may be due to the sample size not being large 376 enough to detect the signal. In addition, a positive association between voriconazole exposure 377 and efficacy may be blurred by the absence of information on the pathogen as well as the disease 378
status. 379
It is acknowledged that it would be beneficial to set up a reference range of voriconazole 380 C min for prescribers if they have the capacity and prefer to do TDM for voriconazole 381 management. For this purpose, a wide range of 1-6 μg/mL is deemed acceptable as the 'typical' 382 is presented elsewhere (17). It is also be noted that approximately 80% of IA patients in this 390 study had voriconazole C min ranging from 1 to 6 μg/mL at 4 mg/kg IV q12h, and approximately 391 85% of patients had C min within this range at 300 mg oral q12h (17) . 392 A few scenarios are described to elaborate how to adjust voriconazole dose if 393 voriconazole C min is taken into consideration. If a patient had a voriconazole C min of 0.5 μg/mL 394 and responded well, it is not necessary to increase the dose. If a patient had a voriconazole C min 395 of 2 μg/mL and was able to tolerate this dose, but the response seemed less than ideal, 396 voriconazole dose could be increased with caution in the hope of improving the chance of 397 clinical success. If a patient had a voriconazole C min of 4 μg/mL and responded well, but 398 treatment-related toxicity was shown (e.g., moderate to severe hepatic AEs), voriconazole dose 399 could be reduced with caution. If a patient had a voriconazole C min of 6.5 μg/mL, had responded 400 well and was able to tolerate this dose (e.g., no hepatic, visual or psychiatric AEs), it is not 401 necessary to reduce the dose. 402
In summary, given the complex clinical situation for patients with serious fungal 403 infections, it is difficult to establish definitive exposure-response relationships for voriconazole. (14) 0.0262 (35) OFV = objective function value, %RSE = percent relative standard error, SURV6 = surviving 6 weeks, AUC a = anidulafungin AUC 0-24 , AUC v = voriconazole AUC 0-12 , C mina = anidulafungin C min , C minv = voriconazole C min , Duranid = anidulafungin treatment duration, TRTG = treatment group (1 = combination, 0 = monotherapy). Table 3 . Model-based predicted probability change by voriconazole and anidulafungin 499 exposures 500
497 498
Analysis type for hepatic AEs % mean increase in probability by 1 μg/mL increment of voriconazole C min in the presence of anidulafungin (median C min of 2.6 μg/mL), Range (%) % mean change in probability by 1 μg/mL increment of anidulafungin C min in the presence of voriconazole (median C min of 3 μg/mL), Range (%) Single-panel data Treatment-related 5 -8 6 -9 All-causality 5 -6 6 -7 Multiple-panel data Treatment-related 4 -10 3 -11 All-causality 3 -9 3 -10 
